AA
YMAB

ALPS Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

ALPS Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,429
Closed -$110K – 1172
2025
Q2 		$110K Sell
24,429
-8,880
-27% -$39.9K ﹤0.01% 1024
2025
Q1 		$148K Sell
33,309
-2,906
-8% -$16.9K ﹤0.01% 972
2024
Q4 		$284K Buy
36,215
+1,984
+6% +$24.2K ﹤0.01% 927
2024
Q3 		$450K Buy
34,231
+7
+0% +$89 ﹤0.01% 623
2024
Q2 		$413K Buy
+34,224
New +$462K ﹤0.01% 627
2022
Q1 		– Sell
-50,503
Closed -$819K – 1014
2021
Q4 		$819K Sell
50,503
-2,906
-5% -$62.1K 0.01% 386
2021
Q3 		$1.52M Sell
53,409
-3,977
-7% -$125K 0.01% 347
2021
Q2 		$1.94M Buy
+57,386
New +$1.84M 0.02% 331
2020
Q4 		– Sell
-51,029
Closed -$1.96M – 885
2020
Q3 		$1.96M Sell
51,029
-3,210
-6% -$128K 0.03% 238
2020
Q2 		$2.34M Buy
+54,239
New +$2.05M 0.03% 224
2019
Q4 		– Sell
-68,175
Closed -$1.78M – 864
2019
Q3 		$1.78M Sell
68,175
-3,400
-5% -$86.9K 0.01% 222
2019
Q2 		$1.64M Buy
+71,575
New +$1.64M 0.01% 254

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ALPS Advisors's YMAB Position: Q3 2025 in Review

ALPS Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 24,429 shares — an estimated $110K sold.

ALPS Advisors first reported a position in YMAB in Q2 2019 and held it in 12 quarters. The position peaked at $2.34M in Q2 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • ALPS Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ALPS Advisors sold 24,429 Y-mAbs Therapeutics shares in Q3 2025, an estimated $110K.
  • ALPS Advisors first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 12 quarters.
  • ALPS Advisors's Y-mAbs Therapeutics position peaked at $2.34M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on ALPS Advisors's 13F filing for Q3 2025, filed 5 Nov 2025.